Natalizumab inhibits lymphocyte trafficking across the blood–brain barrier, reducing relapse rates by up to 70% in patients with relapsing-remitting multiple sclerosis (RRMS). Discontinuation of the drug, usually due to pregnancy or risk of progressive multifocal leukoencephalopathy (PML), can trigger the return of disease activity or, occasionally, a fulminant immune reconstitution inflammatory syndrome (IRIS) as lymphocytes re-enter the CNS.1–3

We describe a case of life-threatening IRIS following natalizumab cessation in pregnancy, but complete clinical rescue with no adverse sequelae following drug restart in the second trimester.

Case report. A 21-year-old woman was diagnosed with RRMS after 2 disabling relapses within 12 months (1 hemiparetic, 1 dorsal cord, each resolving completely within 4 weeks without corticosteroids) and brain MRI consistent with progressive, active demyelination (figure, A,a–c, worst Expanded Disability Status Scale [EDSS] score 3.0). Monthly IV natalizumab (300 mg) was commenced (negative JC virus [JCV] status) and the patient had no further relapses in the next year (EDSS 1.0). She attended clinic for her 15th infusion and reported that she was 8 weeks pregnant: natalizumab was discontinued. At 16 weeks’ gestation (3 months after her last natalizumab infusion), the patient developed rapidly progressive weakness of all 4 limbs over a week. She was hospitalized but deteriorated further, becoming encephalopathic and quadriparietic, with a complex opthalmoplegia and gross ataxia (EDSS 9.5; bedbound and requiring all care). MRI revealed multiple large new lesions within the cerebral white matter, brainstem, and cerebellum, as well as longitudinally extensive lesions throughout the cervical cord (figure, A,d–h). Contrast was not administered due to pregnancy. Lumbar puncture revealed normal opening pressure and CSF constituents, zero cells, and no microorganisms. Routine blood tests (including anti–aquaporin 4) and urinalysis were normal. Treatment was commenced with acyclovir, IV methylprednisolone (1 g/d for 3 days), and supportive care. Fetal viability was confirmed by ultrasonography.

There was only modest improvement after 2 weeks (EDSS 8.0). PML was ruled out after negative JCV PCR on CSF. Acyclovir was stopped following a negative CSF viral PCR screen. EEG showed diffuse encephalopathic changes but no seizure activity. Following further deterioration, a second course of IV methylprednisolone (1 g/d for 5 days) was administered but there was no improvement, the patient continuing to require 24-hour inpatient nursing care (EDSS 9.5). Given the patient’s severe disablement, we restarted monthly natalizumab infusions at 24 weeks’ gestation, and continued enteral prednisolone. Over the following 2 weeks, the patient’s neurologic condition improved dramatically: her encephalopathy lifted, muscle tone and power improved, and balance returned. Further improvements over the next 4 months enabled her to regain independence and return to near baseline (EDSS 4.0; figure, B).

The patient gave birth to a healthy baby girl by elective cesarean section at 40 weeks’ gestation (birthweight 3,500 g; Apgar scores of 9 and 10). The infant required phototherapy for mild neonatal jaundice, but was otherwise well: there was no evidence of hematologic disorders. Follow-up MRI postdelivery showed reduced lesion load (figure). One year later, the patient had improved further: her walking was unimpaired, she had mild ataxia only (EDSS 2.0), and her cognitive abilities had recovered to baseline (Addenbrooke Cognitive Examination score 98/100). She could care for her baby, and had re-entered regular employment. Follow-up MRI of brain and cervical cord showed further improvements (figure, A,m–q).
Figure MRI and disability status of the patient over time

(A) MRI of brain and cervical cord over time. All images are T2-weighted without contrast enhancement except A.g, A.l, and A.p, which are diffusion-weighted (gradient factor b = 1,000 s/mm²). (A.a–A.c) Brain at diagnosis of multiple sclerosis (pre-natalizumab [NTZ]). (A.d–A.h) Brain and cervical cord at presentation during pregnancy 3 months after cessation of NTZ. (A.i–A.l) Brain 6 months after restarting NTZ. (A.m–A.q) Brain and cervical cord 1 year after restarting NTZ. (B) Bar chart of Expanded Disability Status Scale (EDSS) score against time with major events depicted. IVMP = IV methylprednisolone (course number); RRMS = relapsing-remitting multiple sclerosis.
the CNS by natalizumab [peak α4-integrin saturation on lymphocytes is achieved 3 days after initial IV infusion and maintained at >80% for 4 weeks, sufficient to prevent significant CNS transmigration of lymphocytes5,6]; (2) ongoing steroid treatment of CNS inflammation; (3) effective endogenous remyelination mechanisms in this patient (suggested by complete and timely recovery from previous disabling relapses); and (4) early resolution of encephalopathy enabling effective therapy and accelerated recovery.

The decision to suspend or continue natalizumab in pregnancy must consider risks to both fetus and mother. Although the risks to the fetus of natalizumab exposure appear low and reversible, further evidence is required, particularly long-term data on children exposed in utero. Careful counselling at the time of natalizumab initiation in women of childbearing age is imperative.

From ABMU (T.H.M., R.S., S.S., O.R.P.), Morriston Hospital, Swansea; Cardiff University (T.H.M.); and Huysell Dales University Health Board (C.O.), Withybush Hospital, Haverfordwest, UK.

Author contributions: Thomas Massey: study concept and design, data accumulation and interpretation, drafting/revision of manuscript. Rachel Smith: data accumulation and interpretation, revision of manuscript. Shabrena Sadig: data accumulation and interpretation, revision of manuscript. Christopher Overton: data accumulation and interpretation, revision of manuscript. Owen Pearson: study concept and design, data accumulation and interpretation, drafting/revision of manuscript.

Acknowledgment: The authors thank the patient and her family for their assistance with this report.

Study funding: No targeted funding reported.

Disclosure: T. Massey has received support to attend a scientific meeting from Novartis. R. Smith, S. Sadig, and C. Overton report no disclosures relevant to the manuscript. O. Pearson has received honoraria and support to attend scientific meetings, speakers’ fees, and advisory boards from Biogen, Genzyme, Novartis, Teva, Merck Serono, and Roche. Go to Neurology.org for full disclosures. The Article Processing Charge was paid by Cardiff University.

EFFECT OF INTERFERON-FREE THERAPY ON COGNITION IN HCV AND HCV/HIV INFECTION: A PILOT STUDY

Approval of direct-acting antivirals against the hepatitis C virus (HCV) has dramatically changed the management of HCV infection due to high cure rates and a favorable safety profile. Their influence on neurologic aspects is notably relevant, as studies demonstrated active HCV replication within the CNS1 and alterations in cerebral metabolism consistent with neuroinflammatory conditions.2 These findings may be causative for cognitive deficits in HCV-infected patients.3 Similar impairment has been demonstrated in patients coinfected with HIV, with a prevalence as high as 60%.4 Therefore, these patients may particularly benefit from HCV eradication. To date, studies addressing the issue of reversibility of cognitive deficits after HCV therapy are based on interferon treatment, which itself can cause continuing cognitive impairment.5 The important question whether these deficits are indeed reversible after HCV eradication remains unsolved to date.

Methods. We conducted an open observational trial with HCV and HCV/HIV coinfected patients and planned HCV treatment. Patients with liver cirrhosis (defined as fibrosis >12.5 kPa), a history of substance dependence, or cerebral diseases were excluded. HIV-infected patients had to have undetectable plasma HIV levels for at least 6 months. We assessed a comparison group of healthy controls (n = 30) for baseline, but not for follow-up. The neuropsychological test battery

Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient

Thomas H. Massey, Rachel Smith, Shaheena Sadiq, et al.

*Neurology* 2017;88:711-713 Published Online before print January 11, 2017
DOI 10.1212/WNL.0000000000003604

This information is current as of January 11, 2017

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://www.neurology.org/content/88/7/711.full.html">http://www.neurology.org/content/88/7/711.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 7 articles, 4 of which you can access for free at: <a href="http://www.neurology.org/content/88/7/711.full.html##ref-list-1">http://www.neurology.org/content/88/7/711.full.html##ref-list-1</a></td>
</tr>
</tbody>
</table>
| Subspecialty Collections       | This article, along with others on similar topics, appears in the following collection(s): All Demyelinating disease (CNS) http://www.neurology.org//cgi/collection/all_demyelinating_disease_cnns  
Multiple sclerosis http://www.neurology.org//cgi/collection/multiple_sclerosis |
| Permissions & Licensing        | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/misc/about.xhtml#permissions |
| Reprints                       | Information about ordering reprints can be found online: http://www.neurology.org/misc/addir.xhtml#reprintsus |